Join us for the Bionomics webinar featuring Key Opinion Leaders (KOLs) Murray B Stein, MD, MPH, FRCPC (University of California San Diego) and Charlie Taylor, PhD (University of California San Diego) who will discuss the unmet medical need and current treatment landscape for Social Anxiety Disorder (SAD) patients, as well as Bionomics’ ongoing clinical development and Phase 2 study paradigm.

The Bionomics Executive Chairman Errol B De Souza, PhD will provide an overview of their lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor which has received Fast Track designation for the acute treatment of SAD and other anxiety disorders.  Dr. De Souza will also provide an update on the ongoing 150 patient Phase 2 PREVAIL study for the acute treatment of SAD currently targeted for topline data reporting by YE 2022. With its novel mechanism of action, BNC210 also exhibits the potential to serve as a treatment for Post-Traumatic Stress Disorder (PTSD) which is being evaluated in an ongoing Phase 2b ATTUNE Study and for which it has been granted Fast Track designation.

A live Q&A session will follow the formal presentations.